Beta
ManageSearchChatDiscover
400099

The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain

Article

Last updated: 29 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

The first Remodulin® I-jet pump implantation in 
Egypt was performed in 2017 at the Magdy 
Yacoub Aswan Heart Centre. Face flushing, 
headaches, jaw pain, cramping, diarrhea, and pain 
at the insertion site are major side effects of the 
drug. According to clinical studies, site pain 
reaches up to 93% of patients with Remodulin® 
pump. Some patients at Aswan Heart Center want 
to discontinue the treatment because of the intense 
pain

DOI

10.21608/cvrepj.2024.400099

Volume

8

Article Issue

2

Related Issue

52428

Issue Date

2024-12-01

Receive Date

2024-12-26

Publish Date

2024-12-01

Print ISSN

2636-4204

Online ISSN

2636-4212

Article File

CVREPJ4000991733004000.pdf

PDF . 1.3MB

Link

https://cvrepj.journals.ekb.eg/article_400099.html

Detail API

https://cvrepj.journals.ekb.eg/service?article_code=400099

Order

400,099

Type

Abstracts

Type Code

3,139

Publication Type

Journal

Publication Title

Cardiovascular Research Prove Journal

Publication Link

https://cvrepj.journals.ekb.eg/

MainTitle

The Most Recommended Site for Subcutaneous Remodulin® (Treprostinil) Pump to Minimize Patient Pain

Details

Type

Article

Created At

29 Dec 2024